These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 31190675)

  • 21. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study.
    Dhaese SAM; De Kezel M; Callant M; Boelens J; De Bus L; Depuydt P; De Waele JJ
    J Crit Care; 2018 Oct; 47():164-168. PubMed ID: 30005302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of 2020 EUCAST criteria on meropenem prescription for the treatment of Pseudomonas aeruginosa infections: an observational study in a university hospital.
    Munting A; Regina J; Damas J; Lhopitallier L; Kritikos A; Guery B; Senn L; Viala B
    Clin Microbiol Infect; 2022 Apr; 28(4):558-563. PubMed ID: 34826618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.
    Drusano GL; Neely MN; Yamada WM; Duncanson B; Brown D; Maynard M; Vicchiarelli M; Louie A
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa in a Healthcare Setting in Alexandria, Egypt.
    Abaza AF; El Shazly SA; Selim HSA; Aly GSA
    Pol J Microbiol; 2017 Sep; 66(3):297-308. PubMed ID: 29319510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure.
    Solé M; Fàbrega A; Cobos-Trigueros N; Zamorano L; Ferrer-Navarro M; Ballesté-Delpierre C; Reustle A; Castro P; Nicolás JM; Oliver A; Martínez JA; Vila J
    J Antimicrob Chemother; 2015 Nov; 70(11):3004-13. PubMed ID: 26260130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and Preclinical Evaluation of TPA-Based Zinc Chelators as Metallo-β-lactamase Inhibitors.
    Schnaars C; Kildahl-Andersen G; Prandina A; Popal R; Radix S; Le Borgne M; Gjøen T; Andresen AMS; Heikal A; Økstad OA; Fröhlich C; Samuelsen Ø; Lauksund S; Jordheim LP; Rongved P; Åstrand OAH
    ACS Infect Dis; 2018 Sep; 4(9):1407-1422. PubMed ID: 30022668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of metallo beta lactamase producing Pseudomonas aeruginosa in ICU patients.
    Varaiya A; Kulkarni N; Kulkarni M; Bhalekar P; Dogra J
    Indian J Med Res; 2008 Apr; 127(4):398-402. PubMed ID: 18577797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial susceptibility and molecular epidemiological analysis of clinical strains of Pseudomonas aeruginosa.
    Tsuchimochi N; Takuma T; Shimono N; Nagasaki Y; Uchida Y; Harada M
    J Infect Chemother; 2008 Apr; 14(2):99-104. PubMed ID: 18622671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
    El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B
    APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years].
    Nasu Y; Abe M; Ono N; Araki M; Horimi T; Takahashi I
    Jpn J Antibiot; 2004 Oct; 57(5):438-48. PubMed ID: 15655905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of MexAB-OprM and MexXY-OprM efflux pumps and class 1 integrons in resistance to antibiotics in burn and Intensive Care Unit isolates of Pseudomonas aeruginosa.
    Goli HR; Nahaei MR; Rezaee MA; Hasani A; Kafil HS; Aghazadeh M; Nikbakht M; Khalili Y
    J Infect Public Health; 2018; 11(3):364-372. PubMed ID: 28993173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
    Nicolau DP; Carmeli Y; Crank CW; Goff DA; Graber CJ; Lima AL; Goldstein EJ
    Int J Antimicrob Agents; 2012 Jan; 39(1):11-5. PubMed ID: 22047702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of Antipseudomonal Antibiotics and Mechanisms of Multidrug Resistance in Pseudomonas aeruginosa.
    El Zowalaty ME; Gyetvai B
    Pol J Microbiol; 2016; 65(1):23-32. PubMed ID: 27281991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distribution of Pseudomonas-Derived Cephalosporinase and Metallo-β-Lactamases in Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Korea.
    Cho HH; Kwon GC; Kim S; Koo SH
    J Microbiol Biotechnol; 2015 Jul; 25(7):1154-62. PubMed ID: 25907063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of metallo beta-lactamase production and antibiotic resistance with E-test method in pseudomonas, acinetobacter and klebsiella strains, in Turkey.
    Toraman ZA; Yakupogullari Y; Kizirgil A
    J Infect Chemother; 2004 Oct; 10(5):257-61. PubMed ID: 16163458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced efficacy of putative efflux pump inhibitor/antibiotic combination treatments versus MDR strains of Pseudomonas aeruginosa in a Galleria mellonella in vivo infection model.
    Adamson DH; Krikstopaityte V; Coote PJ
    J Antimicrob Chemother; 2015 Aug; 70(8):2271-8. PubMed ID: 25921513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.